🇺🇸 INCB-057643 in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 14

Most-reported reactions

1. Arthralgia — 2 reports (14.29%)
2. Dyspnoea — 2 reports (14.29%)
3. Leukopenia — 2 reports (14.29%)
4. Pain In Extremity — 2 reports (14.29%)
5. Back Pain — 1 report (7.14%)
6. Chest Pain — 1 report (7.14%)
7. Condition Aggravated — 1 report (7.14%)
8. Cough — 1 report (7.14%)
9. Covid-19 — 1 report (7.14%)
10. Lung Opacity — 1 report (7.14%)

Source database →

Frequently asked questions

Is INCB-057643 approved in United States?

INCB-057643 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for INCB-057643 in United States?

Marketing authorisation holder not available in our data.